Now, the growing buzz around the use of GLP-1 medications like Ozempic to treat alcohol use disorder finally has new clinical ...

Researchers looked at the nine people who had vision problems while using the drugs and is one of several that have ...

Ozempic and Wegovy maker Novo Nordisk placed a print ad responding to the Super Bowl spot from competitor Hims & Hers.

If the CMS rule to cover obesity medications is finalized, coverage will increase by other insurers, experts predicted. HHS ...

Independence Blue Cross began limiting coverage of GLP-1 drugs on Jan. 1 to some medical conditions, but not obesity or weight loss.

Hims & Hers hit the bullseye with its Super Bowl ad, sparking a surge in clicks to its site.The ad also hit a nerve with the ...

A recent study found that over a third of websites selling compounded diabetes and weight loss medications, such as Ozempic and Wegovy, falsely claim they are FDA-approved.

From revenue to R&D investment, Novo and Lilly and their mega-blockbuster weight loss drugs Zepbound and Wegovy have moved ...

Can GLP-1 Meds Harm Your Eyes ... who were taking GLP-1s such as semaglutide (Wegovy/Ozempic) and tirzepatide (Mounjaro/Zepbound). Seven of the nine patients developed a condition known as ...

The increased use of drugs like Wegovy and Zepbound is reminiscent of ... and cardiologists are among the specialists flocking to GLP-1 drugs to manage blood sugar and weight.

GLP-1 agonist semaglutide is the active ingredient in Novo Nordisk's blockbuster weight-loss drug Wegovy, which achieved sales of around $8 billion last year. Supply constraints have meant that ...